Loading…
← CockpitCompetitor Analysis › ENTERO.NS Entero Healthcare Solutions LimitedOpen in the cockpit ↗

Entero Healthcare Solutions LimitedENTERO.NSCompetitor analysis, valuation and peers

India · INR·Health Care›Medical Distributors
Momentum leader 98
Mkt cap
$925M
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$5.59M
20-day average traded
Fwd P/E
47.7×
forward earnings
ROIC−WACC
-0.4 pp
WACC 9.2%
Hurdle
-5 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · INR₹1,986
1D+1.0%
1W-0.9%
1M+32.1%
3M+41.0%
6M+60.1%
YTD+93.5%
1Y+75.1%
ATR %4.6%
Beta0.38
52w lowhigh7.1% off high

What Entero Healthcare Solutions does

Employees: 4,970

Entero Healthcare Solutions at a glance

Size Entero Healthcare Solutions (ENTERO.NS) is an India Health Care company (Medical Distributors) with a market value of $925M, the 626th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,986 on 18 Nov 2026.

Performance Over six months the shares gained 60.1%, against -3.7% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 34.8% over the last twelve months (peer median +4.4%); the operating margin is 4.1% (peer median 1.9%).

Valuation It trades at 47.7× forward earnings against a peer median of 14.6× (most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points below its cost of capital (9.2% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026ENTERO.NS 158Peer median 96
Six months, rebased to 100: Entero Healthcare Solutions against the median of its 20 peers (local-currency closes).

Entero Healthcare Solutions financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹76.4B₹65.9B₹51.0B₹39.2B₹33.0B
Revenue growth—+29%+30%+19%—
Gross profit₹5.22B₹3.80B₹2.48B₹1.69B₹1.10B
EBITDA₹3.61B₹2.68B₹1.72B₹1.12B₹640M
Net income₹1.39B₹1.15B₹948M₹391M-₹116M
Free cash flown/a₹17.8M-₹916M-₹986M-₹892M
Capital expendituren/a₹675M₹113M₹54.2M₹55.2M
Total debt₹9.04B₹6.77B₹3.85B₹3.38B₹4.38B

Quarterly statements and history in the cockpit →

Entero Healthcare Solutions competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%6826ARJO-B603368600713301584NEUDOCM74766005873360600628RDC30137060513666170000784104ENTERO.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Entero Healthcare Solutions is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%20×40×6826ARJO-B603368NEU747660058733608129ENTERO.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Entero Healthcare Solutions is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%6826ARJO-B603368301584NEU74766005873360301370605136000078ENTERO.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Entero Healthcare Solutions is the large dot.

Entero Healthcare Solutions competitors and peer comparison

How Entero Healthcare Solutions compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Entero Healthcare Solutions against its 20 peers (data as of 18 Nov 2026)
MeasureENTERO.NSPeer medianRank in peer set
1-month return+32.1%-3.1%highest of 21
6-month return+60.1%-3.7%3rd highest of 21
Distance from 52-week high-7.1%-21.6%3rd highest of 21
Revenue growth (TTM)+34.8%+4.4%highest of 21
Operating margin4.1%1.9%7th highest of 21
Forward P/E47.7×14.6×most expensive of 10
Growth the price implies (Req g, 7 yrs)24.7%-1.2%2nd most demanding of 16
Growth delivered (Del g)+29.9%+5.7%highest of 16
Hurdle (Req g minus delivered)-5.3 pp-6.3 pp8th most demanding of 16
ROIC minus cost of capital-0.4 pp+0.0 pp10th lowest of 21
Net debt / EBITDA1.9×0.2×3rd most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%47.7×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%7.7×17.0%+12.4%
Arjo ARJO-B.STSweden$974M+42%0%8%21.1×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%9.5×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%n/an/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%n/a-2.7%+17.9%
Neuca NEU.WAPoland$795M-9%+8%2%15.3×5.3%+8.1%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%n/an/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%18.4×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%13.4×-6.9%+1.2%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%14.6×-14.5%+7.6%
Arata 2733.TJapan$576M-3%+3%1%12.0×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%n/a-1.6%+1.0%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%n/an/an/a
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%n/a13.1%+7.5%
Toho 8129.TJapan$1.64B-5%+4%1%22.2×-4.6%+5.1%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%n/a21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%n/an/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%n/an/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%n/a58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%n/a-1.2%+5.7%

Questions

Which companies are Entero Healthcare Solutions's closest peers?
The cockpit's peer set: Shanghai Haohai Biological Technology (6826.HK), Arjo (ARJO-B.ST), Guangxi LiuYao (603368.SS), Nanjing Pharmaceutical (600713.SS), Shanghai C and D INNOSTIC Medical Technology (301584.SZ), Neuca (NEU.WA), DocMorris (DOCM.SW), AS ONE (7476.T).
Is Entero Healthcare Solutions expensive compared with its peers?
On forward p/e it trades at 47.7× against a peer median of 14.6×, most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +30%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Entero Healthcare Solutions stock performed?
Over six months to 18 Nov 2026 the shares returned +60.1% against -3.7% for the median peer; over one year +75.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.